Abstract
The severe acute respiratory syndrome coronavirus-2 and related coronavirus disease 2019 (COVID-19) pandemic have deleteriously affected cancer research worldwide, including basic, translational, and clinical fields, because of prolonged shut-down of research laboratories consequent to lockdown restrictions, curtailment of researchers’ laboratory access, decreased availability of patient samples, and clinical trial disruptions.1–5 In addition, cuts in funding are significantly contributing to the impact and are threatening the viability of cancer research as a whole.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
